MeVis publishes figures for financial year 2022/2023 and forecast for
2023/2024

EQS-News: MeVis Medical Solutions AG / Key word(s): Annual Results
MeVis publishes figures for financial year 2022/2023 and forecast for
2023/2024

29.01.2024 / 19:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

* Turnover down by EUR 1.5 million to EUR 17.3 million

* EBIT of EUR 3.9 million, 23% margin

* Earnings after taxes down by EUR 2.9 million to EUR 4.9 million

* Forecast for the 2023/2024 financial year

* Slight increase in sales from EUR 18.0 million to EUR 18.5 million

* EBIT stable at EUR 4.5 million to EUR 5.0 million

Bremen, January 29, 2024 - MeVis Medical Solutions AG (ISIN: DE000A0LBFE4),
a leading medical imaging software company, announces its results for the
fiscal year 2022/2023, with reporting period October 1, 2022 to September
30, 2023.

Revenue in the past financial year 2022/2023 amounted to EUR 17.3 million
(compared to EUR 18.8 million in the financial year 2021/2022). Of the
revenue, 26 % (previous year: 28 %) is attributable to the sale of licenses,
36 % (previous year: 32 %) to maintenance revenue and 38 % (previous year:
38 %) to other revenue, which includes services for and recharges to
affiliated companies and the parent company.

The decline in sales compared to the previous year is mainly due to the
decline in the license business, but also to the postponement of a
development project, which we now expect to start in 2024. Other revenue,
especially development services, fell slightly, while maintenance revenue
continued to develop very positively.

The results are still satisfactory in view of the development of sales. EBIT
(earnings before interest and taxes) of EUR 3.9 million was generated in
2022/2023, compared to EUR 7.9 million in 2021/2022. The EBIT margin fell
accordingly to 23 % compared to the previous year's figure of 42 %.

As a result of the fiscal unity, only low income taxes of EUR 0.1 million were
incurred in the past financial year, identical to the previous year.

This results in earnings after taxes of EUR 4.9 million (28% margin) for the
2022/2023 financial year, compared to EUR 7.8 million (41% margin) in
2021/2022. The profit of EUR 4,920 thousand will be transferred to Varex
Imaging Deutschland AG on the basis of the control and profit transfer
agreement.

For the 2023/2024 financial year, sales are now expected to increase
slightly year-on-year to between EUR 18.0 million and EUR 18.5 million. In
addition to the slight increase in sales with the customer Hologic, sales in
the lung and liver area are also expected to increase slightly. We expect a
slight decline in the area of development services. For earnings before
interest and taxes (EBIT), we expect stability in the range of EUR 4.5 million
to EUR 5.0 million. The forecast slight growth in sales and the simultaneous
increase in personnel costs and other operating expenses are key drivers for
the EBIT outlook.

The half-year financial report for the 2023/2024 financial year will be
published on May 27, 2024.


Contact:
Kirchhoff, Marcus / CEO


---------------------------------------------------------------------------

29.01.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        MeVis Medical Solutions AG
                   Caroline-Herschel-Str. 1
                   28359 Bremen
                   Germany
   Phone:          +49 421 224 95 0
   Fax:            +49 421 224 95 999
   E-mail:         ir@mevis.de
   Internet:       http://www.mevis.de
   ISIN:           DE000A0LBFE4
   WKN:            A0LBFE
   Listed:         Regulated Market in Frankfurt (General Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1825455

End of News EQS News Service
---------------------------------------------------------------------------

1825455 29.01.2024 CET/CEST